Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Eribulin Mesylate for Brain Metastases from Breast Cancer
NCT02581839Phase 2Completed
- Sponsor
- Case Comprehensive Cancer Center
- Start
- Nov 2015
- Primary completion
- Jul 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of eribulin in breast cancer, brain metastases, sponsored by Case Comprehensive Cancer Center. Started Nov 2015; status: completed.
02
Drugs
eribulin
03
Conditions
breast cancerbrain metastases
Beyond the preview
Go deeper on NCT02581839.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02581839.